Estimation of an EORTC QLU-C10 Value Set for Spain Using a Discrete Choice Experiment.
- Published in:
- 2021
- By:
- Publication type:
- journal article
Works matching IS 11707690 AND DT 2021 AND VI 39 AND IP 9
Results: 9
1
2
Correction to: Cost Effectiveness of Ranibizumab vs Aflibercept vs Bevacizumab for the Treatment of Macular Oedema Due to Central Retinal Vein Occlusion: The LEAVO Study.
- Published in:
- 2021
- By:
- Publication type:
- Correction Notice
3
Economic Evidence on Potentially Curative Gene Therapy Products: A Systematic Literature Review.
- Published in:
- PharmacoEconomics, 2021, v. 39, n. 9, p. 995, doi. 10.1007/s40273-021-01051-4
- By:
- Publication type:
- Article
4
Implementing Outcomes-Based Managed Entry Agreements for Rare Disease Treatments: Nusinersen and Tisagenlecleucel.
- Published in:
- 2021
- By:
- Publication type:
- journal article
5
Characterization of the Pharmaceutical Risk-Sharing Arrangement Process in Catalonia.
- Published in:
- PharmacoEconomics, 2021, v. 39, n. 9, p. 973, doi. 10.1007/s40273-021-01046-1
- By:
- Publication type:
- Article
6
Towards Transparency in the Selection of Published Health Utility Inputs in Cost-Utility Analyses: The Health Utility Application Tool (HAT).
- Published in:
- PharmacoEconomics, 2021, v. 39, n. 9, p. 1075, doi. 10.1007/s40273-021-01039-0
- By:
- Publication type:
- Article
7
A Net Benefit Approach for the Optimal Allocation of a COVID-19 Vaccine.
- Published in:
- PharmacoEconomics, 2021, v. 39, n. 9, p. 1059, doi. 10.1007/s40273-021-01037-2
- By:
- Publication type:
- Article
8
Cost Effectiveness of Ribociclib in Combination with Fulvestrant for the Treatment of Postmenopausal Women with HR+/HER2− Advanced Breast Cancer Who Have Received No or Only One Prior Line of Endocrine Therapy: A Canadian Healthcare Perspective.
- Published in:
- PharmacoEconomics, 2021, v. 39, n. 9, p. 1045, doi. 10.1007/s40273-021-01027-4
- By:
- Publication type:
- Article
9
Aspects and Challenges of Resource Use Measurement in Health Economics: Towards a Comprehensive Measurement Framework.
- Published in:
- PharmacoEconomics, 2021, v. 39, n. 9, p. 983, doi. 10.1007/s40273-021-01048-z
- By:
- Publication type:
- Article